As the only Canadian public company focused exclusively on developing stem cell therapeutic technologies, we are uniquely positioned as the commercialization partner of choice for discoveries from basic research in regenerative medicine from Canadian and international research institutions. The volume of research that requires a development partner continues to grow as evidence by the establishment of the McEwen Centre for Regenerative Medicine in 2010 and the Canadian Government-funded Centre for the Commercialization of Regenerative Medicine, a partner with the Canadian Networks of Centres of Excellence in 2011.

Our new team is actively reviewing numerous opportunities in regenerative medicine to augment our existing pipeline of stem cell-based therapies. As one of the few publicly-traded companies worldwide that are focused exclusively on stem cell therapies we already possess a primary benefit of the spin-out process: the prospect of access to capital from public markets.

We represent a unique platform to major academic institutions in their need to convert basic research into products of value for patients with currently untreatable conditions. We have attracted new leadership to the board of directors and management and we are expanding our scientific advisory board, to ensure we have the necessary expertise in the stem cell field to permit us to make informed decisions and an established ability to raise capital to fund development.

We have sufficient cash on hand to fund the search for appropriate in-licensing or acquisition candidates. We believe our public listing and track record within the capital markets provide the necessary components to raise additional capital once we have indentified these candidates.

Research universities and hospitals across Canada are international leaders in the stem cell field and are producing exciting discoveries regularly but they are funded to perform discovery research and are not funded to develop their discoveries beyond preclinical and, to a small degree, early stage human trials.

Our approach is straightforward: assemble a pipeline of attractive stem cell-based candidates with clearly defined milestone events. This clarity, together with our reputation for discipline, will enable us to approach both new and existing investors to fund development through to the event.

Our professional team of drug developers has the clinical experience and the access to the necessary resources to deliver value to shareholders. In any endeavour of significance, the early participants require a great deal of fortitude. It is widely anticipated at the most knowledgeable levels that stem cell research will change the face of how medicine is practiced. Dr. Weiss’ work and his vision have provided us with a great head start in the race to bring stem cell therapies out of the lab and into the commercial market. Our commitment to his vision and this exciting new field is resolute. We have a unique opportunity to be one of the few early participants in the revolution that stem cell-based therapies hold for the practice of medicine, resulting in important outcomes for patients and investors.